CD8A and neoplasm: LOAd703 rapidly increased Ad‐specific antibodies, and boosted Ad‐specific T‐cells, and circulating CD8+ effector memory T‐cells; however, tumor‐specific CD8+ T‐cell responses were not evaluated in this clinical trial [99].